{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:55:20Z","timestamp":1762509320021,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ctro.2020.10.002","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T21:31:57Z","timestamp":1602883917000},"page":"81-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Health-related quality of life after ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: reporting the patient\u2019s perspective"],"prefix":"10.1016","volume":"25","author":[{"given":"Marieke","family":"van Son","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Monninkhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Lagendijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochem","family":"van der Voort van Zyp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ctro.2020.10.002_b0005","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.eururo.2016.05.043","article-title":"Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries","volume":"70","author":"Wong","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ctro.2020.10.002_b0010","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.eururo.2014.09.028","article-title":"The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy","volume":"67","author":"Zumsteg","year":"2015","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ctro.2020.10.002_b0015","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.urolonc.2013.12.014","article-title":"Underutilization of local salvage therapy after radiation therapy for prostate cancer","volume":"32","author":"Tran","year":"2014","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2020.10.002_b0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.ctro.2020.10.002_b0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11934-017-0709-4","article-title":"Salvage therapy options for local prostate cancer recurrence after primary radiotherapy: a literature review","volume":"18","author":"Golbari","year":"2017","journal-title":"Curr Urol Rep"},{"issue":"2","key":"10.1016\/j.ctro.2020.10.002_b0030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.euf.2015.09.004","article-title":"Comparative oncologic and toxicity outcomes of salvage radical prostatectomy versus nonsurgical therapies for radiorecurrent prostate cancer: a meta-regression analysis","volume":"2","author":"Philippou","year":"2016","journal-title":"Eur Urol Focus"},{"issue":"10","key":"10.1016\/j.ctro.2020.10.002_b0035","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/jamaoncol.2016.5840","article-title":"Imaging locally advanced, recurrent, and metastatic prostate cancer: a review","volume":"3","author":"Lindenberg","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctro.2020.10.002_b0040","doi-asserted-by":"crossref","unstructured":"Patel P, Mathew MS, Trilisky I, Oto A. Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer. Radiographics : a review publication of the Radiological Society of North America, Inc. 2018;38(2):437-49.","DOI":"10.1148\/rg.2018170147"},{"issue":"11","key":"10.1016\/j.ctro.2020.10.002_b0045","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00345-016-1811-9","article-title":"Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review","volume":"34","author":"Duijzentkunst","year":"2016","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.ctro.2020.10.002_b0050","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.21037\/tau.2019.08.21","article-title":"A systematic review of salvage focal therapies for localised non-metastatic radiorecurrent prostate cancer","volume":"9","author":"Khoo","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"16","key":"10.1016\/j.ctro.2020.10.002_b0055","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.ejca.2008.07.030","article-title":"An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer","volume":"44","author":"van Andel","year":"2008","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2020.10.002_b0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clinical Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2020.10.002_b0065","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1177\/1533034617741797","article-title":"Focal MRI-guided salvage high-dose-rate brachytherapy in patients with radiorecurrent prostate cancer","volume":"16","author":"Maenhout","year":"2017","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ctro.2020.10.002_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2020.01.023","article-title":"MRI-guided ultrafocal salvage high-dose-rate brachytherapy for localized radiorecurrent prostate cancer: updated results of 50 patients","author":"van Son","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2020.10.002_b0075","doi-asserted-by":"crossref","DOI":"10.1177\/1179554917738765","article-title":"Salvage low dose rate brachytherapy for recurrent prostate cancer after external beam radiotherapy: results from a single institution with focus on toxicity and functional outcomes","volume":"11","author":"Barbera","year":"2017","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2020.10.002_b0080","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.juro.2016.06.092","article-title":"Pathological, oncologic and functional outcomes of a prospective registry of salvage high intensity focused ultrasound ablation for radiorecurrent prostate cancer","volume":"197","author":"Siddiqui","year":"2017","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.ctro.2020.10.002_b0085","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1442-2042.2011.02815.x","article-title":"Health-related quality of life after salvage high-intensity focused ultrasound (HIFU) treatment for locally radiorecurrent prostate cancer","volume":"18","author":"Berge","year":"2011","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.ctro.2020.10.002_b0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.radonc.2014.06.013","article-title":"Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life","volume":"112","author":"Peters","year":"2014","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2020.10.002_b0095","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ijrobp.2018.06.039","article-title":"Focal salvage high dose-rate brachytherapy for locally recurrent prostate cancer after primary radiation therapy failure: results from a prospective clinical trial","volume":"102","author":"Murgic","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctro.2020.10.002_b0100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.radonc.2007.07.018","article-title":"Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review","volume":"84","author":"van der Wielen","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2020.10.002_b0105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"146","author":"Morton","year":"2020","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2020.10.002_b0110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.radonc.2016.10.019","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy","volume":"122","author":"Morton","year":"2017","journal-title":"Radiother Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630820300823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630820300823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:08:09Z","timestamp":1762502889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630820300823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":22,"alternative-id":["S2405630820300823"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2020.10.002","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life after ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: reporting the patient\u2019s perspective","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2020.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}]}}